Stock Market & Financial Investment News

News Breaks March 13, 2012 05:46 EDT PFE Biocon, Pfizer end commercialization agreement Biocon and Pfizer announced the conclusion of their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products. The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently. News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 16, 2013 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 10, 2013 16:29 EDT PFE On The Fly: Closing Wrap Subscribe for More Information 12:31 EDT PFE On The Fly: Midday Wrap Subscribe for More Information 11:48 EDT PFE Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 09:21 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:08 EDT PFE Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. 07:46 EDT PFE DURECT says additional clinical studies needed for Remoxy DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. Sign up for a free trial to see the rest of the stories you've been missing.